With the annual Personalized Medicine World Conference (PMWC) right around the corner, it's a good time to reflect on where we stand in terms of reaching personalized medicine. How close are we, actually? What barriers do we have to overcome so that patients can receive the benefits of tailored therapy at their bedside? How much optimism should we have about the current state of personalized medicine?
Bina Technologies News
One of the elements lacking in the personalized medicine discussion today is the perspective of clinicians and informaticists working in the field. To remedy the gap, I've asked a series of leaders in the industry to offer up their views.
Read more at FierceBiotech.
Introducing the Bina Genomic Analysis Platform
Bina Technologies, Inc. is a leader in ultra-fast genomic data analysis with the ability to process a 40X whole human genome in less than 4 hours. Our Genomic Analysis Platform is not only fast but very accurate. Using our innovative platform we have been able to accelerate the popular BWA aligner combined with the Broad Institute’s Genome Analysis Toolkit. In this webinar, Amirhossein Kiani and Hugo Lam will discuss how we're able to achieve ultra-fast, scalable, and highly accurate genomic data analysis.
View Recorded Webinar
Bina Technologies is testing out their Bina Genomic Analysis Platform in college campuses. The Bina Genomic Analysis Platform is a machine that can perform complex whole genome data analysis in four hours or less. It’s like a vending machine for scientists.
Analysis of genomes, which contain an organism’s hereditary information, and exomes, a portion of the genome, is an important part of a scientist or researcher’s work in the field of personalized medicine, and the process normally takes time and requires expensive equipment that not all researchers have easy access to.
As college students make their way back to campus this week, they might find a peculiar vending machine posted up around the biology department. A Palo Alto company is doing university pilots with a series of machines that dole out super complex data computations to passersby, democratizing access to computing power which was, for many schools or individual students, financially unreachable.
The machines analyze both full genome sequences and exomes, or portions of genomes (typically 1 to 2 percent) where 85% of common diseases stemming from malformed proteins and erratic genetic code tend to surface. The jury’s still out about whether repeatedly sequencing exomes is as scientifically rigorous as sequencing the whole genome, but exome analysis is faster and cheaper--Bina’s machine claims to do it in 30 minutes.
Bina Technologies has launched two new capabilities making their big data genomics platform accessible to more users. Whole Exome Analysis and Bina On-Demand expand the user base for the company’s hardware appliance that quickly handles assembly and alignment of raw reads and variant calling in next generation sequencing.
Bina, which launched in 2012, sells a product called the Bina Genomic Analysis Platform. It’s a box full of hardware and algorithms designed to run optimally together, a pairing the company says allows the Bina platform to be faster and more thorough than alternative methods. The Stanford genetics department is using a Bina appliance, Founder and CEO Narges Bani Asadi told me, and has improved its turnaround time on analyzing a single genome by 100 times.
Bina Technologies is focused on optimizing what’s called secondary analysis, the essential data-crunching step that happens immediately after the DNA sequence comes off the next-gen sequencer. That step requires software that first aligns an individual’s DNA sequence with a reference sequence and then picks out the differences between that individual’s sequence and the reference (a process known as variant-calling).
Read more at Biomedical Computation Review.
Bina Technologies, a company aiming to make genome processing faster and cheaper, has accepted $1.75 million for its Series B round, which included $6.25 million from Sierra Ventures. Behind the new capital are Jerry Yang of AME Cloud Ventures and Mohsen Moazami of Columbus Nova Technology Partners.
Bina Technologies Inc ., developer of an analytics platform to help scientists analyze genetic information, has closed its Series B round at $8 million after two new investors joined the financing, VentureWire has learned.
The add-on was provided by AME Cloud Ventures and Columbus Nova Technology Partners, and follows a March raise of $6.25 million in Series B funding from Sierra Ventures and other investors, Chief Executive Narges Bani Asadi said.
The Redwood City, Calif., company also raised a $1.1 million Series A round from individuals in 2011, VentureWire records show.
As gene sequencing becomes more affordable and widespread, demand is rising for products that can analyze and present genetic information back to doctors.